98%
921
2 minutes
20
Hepatitis delta virus (HDV) is geographically classified according to eight known genotypes. The combined hepatitis B-hepatitis D (HEPB-HEPD) disease is the severest form of chronic viral hepatitis in humans and is characterized by mortality rates of ~20%. Hepatitis delta virus has no FDA approved therapy and its only available vaccine is the one for HEPB. Because it is the smallest RNA virus known to infect humans, RNA folding predictions by energy minimization of the whole genome can reveal important information on functional RNA secondary structure elements within the genome. A public HDV database (HDVdb) contains 512 HDV strains on which various bioinformatics methods can be applied, aiming to detect strains that could perform RNA editing via conformational switching. Up to date, only one such strain from HDVdb was known to perform that, in HDV genotype 3. Our goal was to locate more such strains, both in genotype 3 and in other possible HDV genotypes. In past work, by an eigenvalue mathematical analysis, we made an initial prediction that this peculiar RNA editing mechanism also exists in HDV genotype 7. We hereby extend our earlier findings and present newly discovered HDV strains from multiple genotypes for further analysis of RNA editing sites within the virus. The relevant strains taken from HDVdb are from both genotype 3 of Peru and genotype 7 of Cameroon. Additionally, the new strains have a variety of optional RNA editing sites that we report, many of which are unknown to date.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406691 | PMC |
http://dx.doi.org/10.1093/bib/bbaf451 | DOI Listing |
PLoS One
September 2025
Department of Hygiene, Kawasaki Medical School, Kurashiki, Japan.
T-cell therapies have proven to be a promising treatment option for cancer patients in recent years, especially in the case of chimeric antigen receptor (CAR)-T cell therapy. However, the therapy is associated with insufficient activation of T cells or poor persistence in the patient's body, which leads to incomplete elimination of cancer cells, recurrence, and genotoxicity. By extracting the splice element of PD-1 pre-mRNA using biology based on CRISPR/dCas13 in this study, our ultimate goal is to overcome the above-mentioned challenges in the future.
View Article and Find Full Text PDFBrain
September 2025
Central European Institute of Technology Masaryk University (CEITEC MU), 625 00 Brno, Czech Republic.
Mutations in the human ADAR gene encoding adenosine deaminase acting on RNA 1 (ADAR1) cause Aicardi-Goutières syndrome 6 (AGS6); a severe auto-inflammatory encephalopathy with aberrant interferon (IFN) induction. AdarΔ2-13 null mutant mouse embryos lacking ADAR1 protein die with high levels of IFN-stimulated gene (ISG) transcripts. In Adar Mavs double mutants also lacking the Mitochondrial antiviral signaling (MAVS) adaptor, the aberrant IFN induction is prevented.
View Article and Find Full Text PDFNAR Cancer
September 2025
Department of Molecular Biology, Umeå University, 901 87 Umeå, Sweden.
Epitranscriptomic modifications regulate gene expression and have been implicated in cancer, including breast cancer. Using the SCAN-B cohort, we analyzed 49 messenger RNA modification regulators (mRMPs) across breast cancer subtypes. In the basal subtype, we found significant overexpression of mA readers (IGF2BP1-3), mC regulators (NSUN5, ALYREF, YBX1, YBX2), pseudouridine [PUS1, MARS (or MetRS), RPUSD2], and RNA editing enzymes [APOBEC3A (A3A), A3G, ADAR1], all linked to poor survival.
View Article and Find Full Text PDFMol Ther Nucleic Acids
September 2025
Department of Genetics and Biotechnology, College of Life Sciences, Kyung Hee University, Yongin-si, Gyeonggi-do 17104, Republic of Korea.
Epigenetic modulation enables precise gene regulation without altering DNA sequences. While histone acetylation has been widely utilized for gene activation, the therapeutic potential of histone methylation remains underexplored. In this study, we developed a new epigenetic activator by fusing the histone methyltransferase SETD7 to deactivated Cas9 (dCas9).
View Article and Find Full Text PDFMol Ther Nucleic Acids
September 2025
State Key Laboratory of Common Mechanisms Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou 215123, China.
Adenine base editors (ABEs) enable efficient A-to-G base conversions in genomic DNA, serving as powerful tools for basic research and clinical disease treatment. TadA-8e with high processive and compatibility makes ABE8e to be the most widely used adenine base editor and has also facilitated the creation of more elegant base editors based on TadA-8e fusion, such as AYBE and eA&C-BEmax. However, ABE8e has more off-target events including DNA off-target and RNA off-target, which raises safety concerns for precision gene editing.
View Article and Find Full Text PDF